Close Menu

NEW YORK – Clinical state immunotherapy company UbiVac said on Tuesday that it is collaborating with Bristol Myers Squibb on a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a cancer vaccine with a T cell agonist and a PD-1 checkpoint inhibitor.

The Phase IB trial will test whether UbiVac's investigational cancer vaccine DPV-001 combined with BMS' T cell agonist BMS-986178 and nivolumab (Opdivo) can stimulate anti-cancer immunity in advanced triple-negative breast cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.